The global vaccine roll-out has been an ugly free-for-all which is leaving some countries behind
The Oxford/AstraZeneca Covid-19 vaccine in a syringe before being administered.
Evolutionary pressures accompanying the spread of the coronavirus have driven the Covid-19 pandemic into a phase in which new variants are starting to pop up everywhere. In response, governments around the world are racing to vaccinate enough people to achieve herd immunity before the virus acquires a mutation that nullifies existing vaccines’ effectiveness. Sadly, in many emerging and developing economies, this race is being lost, leaving everyone vulnerable to new strains. But it doesn’t have to be this way.
The global deployment of Covid-19 vaccines has so far been an ugly free-for-all, with rich and large countries winning out. At this point, many emerging and developing economies probably will not achieve meaningful levels of vaccination until the end of this year, at the earliest. And many of these countries may never get vaccines that have already been pre-purchased, because manufacturers have massively overpromised what they can deliver. Worse, there is now a distinct possibility that the vaccines, even if they do arrive, will no longer be effective, owing to the proliferation of new variants.
